Tedatioxetine

Tedatioxetine
Clinical data
Other names	Lu AA24530; Lu-AA-24530
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine;
CAS Number	508233-95-2 ;
PubChem CID	9878913;
ChemSpider	8054590 ;
UNII	5H681S8O3S;
KEGG	D10170 ;
CompTox Dashboard (EPA)	DTXSID801029350 ;
Chemical and physical data
Formula	C18H21NS
Molar mass	283.43 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C=C1)=CC=C1SC2=C(C3CCNCC3)C=CC=C2;
	InChI InChI=1S/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3 ; Key:CVASBKDYSQKLSO-UHFFFAOYSA-N ;
	(what is this?) (verify)

Tedatioxetine (Lu AA24530) is an antidepressant that was discovered by scientists at Lundbeck; in 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine.^[1]

Tedatioxetine is reported to act as a triple reuptake inhibitor (5-HT > NE > DA) and 5-HT_2A, 5-HT_2C, 5-HT₃ and α_1A-adrenergic receptor antagonist.^[2]^[3]^[4]^[5]

As of 2009, it was in phase II clinical trials for major depressive disorder,^[5] but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck's product pipeline.^[6]^[7]

On May 10, 2016, all work on tedatioxetine stopped.^[8]

A Sino Patent manages to show that there has been interest in this compound outside of Lundbeck: WO 2015090160

References

^ Daniel Beaulieu for First Word Pharma. September 5th, 2007 Lundbeck, Takeda enter strategic alliance for mood disorder, anxiety drugs
^ "Patent US20100144788 - 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression". Retrieved 7 April 2014.
^ Stephen M. Stahl (19 May 2008). Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. p. 206. ISBN 978-0-521-88663-5. Retrieved 22 November 2011.
^ Ian P. Stolerman (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105. ISBN 978-3-540-68698-9. Retrieved 22 November 2011.
^ ^a ^b "Lu AA24530 shows positive results in major depressive disorder phase II study - FierceBiotech".
^ "Pipeline of Lundbeck". Retrieved 25 August 2013.
^ UK Medicines Information Tedatioxetine entry in UKMI. Page accessed January 20, 2016
^ "Tedatioxetine - AdisInsight". adisinsight.springer.com. Retrieved 2016-06-09.

External links

Lu AA24530 shows positive results in major depressive disorder phase II study

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Daniel Beaulieu for First Word Pharma. September 5th, 2007 Lundbeck, Takeda enter strategic alliance for mood disorder, anxiety drugs

[urlUSPTO20100144788-2] "Patent US20100144788 - 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression". Retrieved 7 April 2014.

[Stahl2008-3] Stephen M. Stahl (19 May 2008). Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. p. 206. ISBN 978-0-521-88663-5. Retrieved 22 November 2011.

[Stolerman2010-4] Ian P. Stolerman (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105. ISBN 978-3-540-68698-9. Retrieved 22 November 2011.

[Fierce-5] "Lu AA24530 shows positive results in major depressive disorder phase II study - FierceBiotech".

[urlPipeline_of_Lundbeck-6] "Pipeline of Lundbeck". Retrieved 25 August 2013.

[7] UK Medicines Information Tedatioxetine entry in UKMI. Page accessed January 20, 2016

[8] "Tedatioxetine - AdisInsight". adisinsight.springer.com. Retrieved 2016-06-09.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

See also

References

External links